[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"advanced-liver-fibrosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:advanced-liver-fibrosis":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,58],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":4},"100651885","prospective-evaluation-of-hepatocellular-carcinoma-surveillance-in-at-risk-patients-screening-hcc-100651885",false,"NCT07764835","Prospective Evaluation of Hepatocellular Carcinoma Surveillance in At-Risk Patients (Screening HCC)","Prospective Evaluation of Hepatocellular Carcinoma Surveillance in At-Risk Patients Using Semiannual Ultrasound LI-RADS and Alpha-Fetoprotein: A Multicenter Real-World Observational Study","Screening HCC","Inclusion Criteria:\n\n* Written informed consent.\n* Age 18 years or older.\n* Liver cirrhosis of any etiology.\n* Chronic hepatitis B with moderate or high risk of HCC according to PAGE-B criteria.\n* Non-cirrhotic chronic liver disease with increased risk for HCC, including fibrosis stage 3 or higher or metabolic dysfunction-associated steatotic liver disease (MASLD) with one or more risk factors for HCC.\n* Followed at hepatology clinics within the Rede D'Or health network.\n* Eligible for routine HCC surveillance with ultrasound and alpha-fetoprotein according to standard clinical practice.\n\nExclusion Criteria:\n\n* Known hepatocellular carcinoma at enrollment.\n* Previous diagnosis of hepatocellular carcinoma.\n* Metastatic liver disease.\n* Other malignant liver tumors present at enrollment.\n* Clinical condition preventing routine surveillance follow-up.\n* Inability to provide informed consent.","ALL","18 Years",{"count":20,"type":21},300,"ESTIMATED","36 Months","OBSERVATIONAL","This prospective multicenter observational study evaluates the performance of a structured hepatocellular carcinoma (HCC) surveillance program in patients at increased risk of developing liver cancer. Participants will undergo routine surveillance with semiannual abdominal ultrasound reported using the Ultrasound Liver Imaging Reporting and Data System (US LI-RADS) and serum alpha-fetoprotein (AFP) testing as part of standard clinical care. The study aims to assess HCC detection rates, stage at diagnosis, detection of other hepatic malignancies, and the time intervals between detection, diagnosis, and treatment in a real-world setting. Approximately 300 participants will be enrolled and followed for up to 36 months.",[26,27,28,29,30],"Hepatocellular Carcinoma","Liver Cirrhosis","Chronic Hepatitis B","Metabolic Dysfunction-Associated Steatotic Liver Disease","Advanced Liver Fibrosis",[32,26,33,34,35,36,37,38,27,28,39,29,40,41,42,43,44,45],"HCC","Liver Cancer","HCC Surveillance","US LI-RADS","Ultrasound LI-RADS","Alpha-Fetoprotein","AFP","MASLD","Real-World Study","Observational Study","Early Detection","BCLC","Rede D'Or","Brazil","NOT_YET_RECRUITING","2026-08-10",{"date":49,"type":50},"2026-08-14","ACTUAL",{"date":52,"type":21},"2026-09-15",{"date":54,"type":21},"2029-06-30",{"name":56,"class":57},"D'Or Institute for Research and Education","OTHER",{"id":59,"slug":60,"hasResults":11,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":66,"targetDuration":4,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":74,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":86},"100375766","phase-2-erlotinib-for-hepatocellular-carcinoma-chemoprevention-100375766","NCT04172779","Erlotinib for Hepatocellular Carcinoma Chemoprevention","Phase II Clinical Trial of Low-dose Erlotinib for Hepatocellular Carcinoma Chemoprevention","ECHO-B","Inclusion Criteria:\n\n* Adults (≥ 18 years-old)\n* Clinically and\u002For histologically diagnosed advanced liver fibrosis or cirrhosis\n* No active hepatic decompensation\n* No prior history of HCC\n* FIB-4 index \\> 3.25\n* PLSec score ≥ 3\n* Adequate hematologic, hepatic, and renal function, Karnofsky performance status score ≥70\n* Both sexes and all racial\u002Fethnic groups will be considered\n\nExclusion Criteria:\n\n* Prior treatment with epidermal growth factor receptor (EGFR) inhibitors\n* Uncontrolled intercurrent, use of CYP3A4 modulators\n* Erlotinib treatment \\\u003C4 weeks or \\\u003C80% of planned regimen at the end of week 4\n* HCC development during the study",{"count":67,"type":21},60,"INTERVENTIONAL",[70],"PHASE2","This phase II randomized placebo-controlled trial studies low-dose erlotinib treatment to assess its efficacy and safety to prevent development of hepatocellular carcinoma in patients with advanced liver fibrosis or cirrhosis.",[73,30],"Cirrhosis, Liver",[75,76],"hepatocellular carcinoma","chemoprevention","2026-06-20",{"date":79,"type":50},"2026-06-24",{"date":81,"type":21},"2026-12",{"date":83,"type":21},"2030-08",{"name":85,"class":57},"University of Texas Southwestern Medical Center",1]